Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine, and Docetaxel for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: Updated Systematic Review and Meta-Analysis
Jubin E Matloubieh, David Hanelin, Ilir Agalliu, Giorgio Treglia, Ursula Maria Vogl · 2024
Read Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine, and Docetaxel for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: Updated Systematic Review and Meta-Analysis by Jubin E Matloubieh, David Hanelin, Ilir Agalliu, Giorgio Treglia, Ursula Maria Vogl (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11674742.txt.
Description
Bladder cancer that has not yet invaded muscle comes back stubbornly often, and washing the bladder with drugs after surgery is the standard defense. Jubin Matloubieh and co-authors update the comparison of three wash drugs in a 2024 pooled review: mitomycin C, gemcitabine, and docetaxel.
Forty-nine studies from 2009 to 2022, trials and cohorts, fed the pooling. Against other treatments, gemcitabine cut recurrence risk by about a quarter and mitomycin by over a third, both statistically firm. Recurrence-free survival analyses ran alongside. Docetaxel's smaller literature was weighed in the same frame. The authors sort single drugs and combinations by recurrence and progression, giving doctors a current league table for a decision made in nearly every bladder practice.
Catalog record
| CREATOR | Jubin E Matloubieh, David Hanelin, Ilir Agalliu, Giorgio Treglia, Ursula Maria Vogl |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |